Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.

about

Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.

Item

http://www.wikidata.org/entity/Q43461603

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Treatment durability, effectiv ...... t-naïve HIV-infected patients.

@en

Treatment durability, effectiv ...... t-naïve HIV-infected patients.

@nl

type

Item

label

Treatment durability, effectiv ...... t-naïve HIV-infected patients.

@en

Treatment durability, effectiv ...... t-naïve HIV-infected patients.

@nl

prefLabel

Treatment durability, effectiv ...... t-naïve HIV-infected patients.

@en

Treatment durability, effectiv ...... t-naïve HIV-infected patients.

@nl

P1476

Treatment durability, effectiv ...... t-naïve HIV-infected patients.

@en

P2093

A Rachlis

http://www.w3.org/2001/XMLSchema#string

B Trottier

http://www.w3.org/2001/XMLSchema#string

C Tremblay

http://www.w3.org/2001/XMLSchema#string

F Boulerice

http://www.w3.org/2001/XMLSchema#string

J G Baril

http://www.w3.org/2001/XMLSchema#string

J S Sampalis

http://www.w3.org/2001/XMLSchema#string

M Loutfy

http://www.w3.org/2001/XMLSchema#string

R Lalonde

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.

Atazanavir: a novel HIV-1 protease inhibitor.

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

HIV protease inhibitors: recent clinical trials and recommendations on use.

Clinical pharmacology, efficacy and safety of atazanavir: a review.

Antiretroviral therapy with heart.

96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients.

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

P304

151-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HCT1203-151

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21684855

http://www.w3.org/2001/XMLSchema#string